美国Xencor
美国Xencor公司2006年3月宣布，通过使用专有的“XmAb”技术在单克隆抗体的稳定区（Fc）导入变异，增强Fc受体的亲和性及特异性，因此把对靶细胞的抗体依赖性细胞毒性（ADCC）的活性成功地在in vitro实验提高到100倍、在in vivo实验提高到10倍以上。研究得到的结果有望增强已经确定了靶细胞的癌症的治疗效果。


Xencor has built one of the most powerful protein engineering technology platforms in the biotechnology industry. Its versatility is evidenced by our success in developing two classes of superior protein drug candidates: XmAb® antibody therapeutics and XPro™ protein therapeutics. Because we can engineer the affinity and specificity of protein-protein interactions, we generate entirely new therapeutic mechanisms of action.

In collaboration with our partners—including leading pharmaceutical companies Boehringer Ingelheim, Centocor, and Pfizer—we are selectively designing next-generation protein drug candidates with superior pharmacological properties and novel molecular compositions. Our internal pipeline of next-generation antibodies and protein therapeutics for cancer, inflammation and autoimmune disease address well understood and validated targets with improved selectivity, efficacy, safety and dosing convenience.